Covid 19 Research using Clinical Trials (Home Page)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
|
Name (Synonyms) |
Correlation |
drug1876 | Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation Wiki | 0.71 |
Correlated MeSH Terms (5)
Correlated HPO Terms (1)
|
Name (Synonyms) |
Correlation |
HP:0011947 | Respiratory tract infection HPO | 0.14 |
There are 2 clinical trials
Clinical Trials
Elderly, hypertension, diabetes and cardiovascular diseases are risk factors for COVID-19
morbility and mortality. However, the real reason for this is not yet understood. It is well
documented that gut microbiota has a critical role in health, particularly in the immune
system and therefore, we propose that gut microbiota composition could affect vulnerability
and disease outcomes of COVID-19.
NCT04355741 COVID-19 Other: Exposure
Primary Outcomes
Measure: Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity. Time: Stool samples of COVID-19 patients will be collected after subject enrollment (single point collection)
Secondary Outcomes
Measure: Differences in gut microbiota composition between COVID-19 patients in relation to mortality. Time: Through study completion, an average of 3 months.
Measure: Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals. Time: Through study completion, an average of 3 months.
Measure: Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation. Time: Through study completion, an average of 3 months.
Vitamin D deficiency has been linked to hypertension, autoimmune, infectious and
cardiovascular diseases which are risk factors for COVID-19. Moreover, COVID-19 patients have
a very high prevalence of hypovitaminosis D (Turin data). Taken together, we aim to
investigate whether genetic variants in vitamin D-related genes contribute to a poor COVID-19
outcome, particularly in hypertension and CV patients, proposing thus a personalized
therapeutics based on vitamin D supplementation in order to reduce the severity and deaths.
NCT04370808 COVID-19 Other: Exposure
Primary Outcomes
Measure: Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity. Time: Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).
Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity. Time: Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).
Secondary Outcomes
Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to mortality. Time: Through study completion, an average of 3 months.
Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals. Time: Through study completion, an average of 3 months.
Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation. Time: Through study completion, an average of 3 months.
Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality. Time: Through study completion, an average of 3 months.
Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals. Time: Through study completion, an average of 1 year.
Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation. Time: Through study completion, an average of 3 months.
No related HPO nodes (Using clinical trials)